Cornell University College of Veterinary Medicine has begun a clinical study evaluating a once-weekly GLP-1–based weight-management therapy for overweight cats. Developed by Akston, the protein treatment aims to help regulate feline appetite and will be tested over about three months in client-owned cats. The study follows preclinical work at Cornell showing no observed adverse effects and pharmacokinetics supporting weekly dosing.

Feline excess weight reportedly remains a widespread health issue, with 61 percent of U.S. cats classified as overweight or obese in 2022. Enrollment is now underway, with plans to recruit at least 70 cats. Akston is also reportedly pursuing a similar GLP-1 program for dogs, currently about six months behind the feline effort.

For more information, visit the Akson website.